RPCEC00000088已完成3 期
Effectiveness and Safety of use ior EPOCIM in the prophylaxis or treatment of anemia in the premature infant. Phase III
Center of Molecular Immunology(CIM)0 个研究点目标入组 72 人开始时间: 2009年10月22日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study. Masking: Open. Control Group: Uncontrolled. Assignment: Single Group. Purpose: Treatment
入排标准
- 年龄范围
- 8 days of birth 至 none（—）
- 性别
- All
入选标准
- •1.Preterm patients with weight = 1500 g and gestational age <34 weeks(determined by the method of date of last menstrual period). 2.Patients whose parent or responsible family has given its consent for participation in the study in writing.
- •3.Patients with more than 7 days old.
- •4.Patients with an intake of at least 50 ml/kg/ day of milk and/or artificial.
排除标准
- •1.Patients with hemolytic or hemorrhagic disease.
- •2.Patients diagnosed with major congenital malformation requiring transfer to another department of Neonatology.
- •3.Patients with known hypersensitivity to products derived from cells above or hypersensitivity to human albumin.
研究者
相似试验
暂停
2 期
Effect and Safety of ior® EPOCIM in patients with Non-Hodking Lymphoma treated with anthracyclines.Patients with Non-Hodking LymphomaRPCEC00000096Center of Molecular Immunology88
招募中
3 期
Investigating the effect of empagliflozin in heart failure in HIV patientsIRCT20130719014054N2Tehran University of Medical Sciences128
已完成
4 期
Effectiveness and Safety of ior EPOCIM in patients with Chronic Renal Failure on dialysis methods.Chronic Renal Insufficiency.RPCEC00000082Center of Molecular Immunology(CIM)621
招募中
Unknown
Evaluation of the efficiency and safety of imeglimin on insulin secretion ability and insulin sensitivity in the treatment of type 2 diabetes mellitustype 2 diabetesJPRN-UMIN000053150Department of Diabetes and Metabolism,Tohto Clinic30
招募中
4 期
Effectiveness and safety of ior®EPOCIM in Chronic Kidney Disease patients in pre-dialysis.Anemia secondary to Chronic Kidney DiseaseRPCEC00000123CIMAB-Center of Molecular Immunology (CIM)425